Q1 2023 Results

Company overview Financial review Innovation: Pipeline overview Financial performance Cardiovascular Immunology RydaptⓇ - Multi-targeted kinase inhibitor NCT03591510 (CPKC412A2218) Indication Acute myeloid leukemia, pediatrics Phase 2 Conclusions Neuroscience Phase Patients 20 Primary Outcome Measures Arms Intervention Target Patients Occurrence of dose limiting toxicities Safety and Tolerability Chemotherapy followed by Midostaurin Newly diagnosed pediatric patients with FLT3 mutated acute myeloid leukemia (AML) Readout Milestone(s) 2026 Publication TBD Appendix Innovation: Clinical trials Oncology References Abbreviations Other 78 Investor Relations | Q1 2023 Results NOVARTIS | Reimagining Medicine

View entire presentation